Molecular Partners AG Net Assets
Molecular Partners AG net assets. Based on the latest financial reports, Molecular Partners AG (MOLN) has net assets worth CHF58.54 Million CHF (≈ $74.02 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF75.70 Million ≈ $95.70 Million USD) and total liabilities (CHF17.15 Million ≈ $21.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Molecular Partners AG net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF58.54 Million |
| % of Total Assets | 77.34% |
| Annual Growth Rate | 4.33% |
| 5-Year Change | -25.12% |
| 10-Year Change | -40.84% |
| Growth Volatility | 74.64 |
Net Assets of Molecular Partners AG (2013–2025)
Net assets of Molecular Partners AG from 2013 to 2025. This chart illustrates how Molecular Partners AG's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Molecular Partners AG to measure how much of total assets are equity-financed.
Annual Net Assets for Molecular Partners AG (2013–2025)
The table below shows the annual net assets of Molecular Partners AG from 2013 to 2025. For live market cap and overall valuation, see MOLN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF80.33 Million ≈ $101.56 Million |
-43.28% |
| 2024-12-31 | CHF141.64 Million ≈ $179.07 Million |
-19.72% |
| 2023-12-31 | CHF176.43 Million ≈ $223.05 Million |
-24.98% |
| 2022-12-31 | CHF235.17 Million ≈ $297.31 Million |
+119.19% |
| 2021-12-31 | CHF107.29 Million ≈ $135.64 Million |
+0.06% |
| 2020-12-31 | CHF107.22 Million ≈ $135.56 Million |
+98.05% |
| 2019-12-31 | CHF54.14 Million ≈ $68.45 Million |
-40.96% |
| 2018-12-31 | CHF91.70 Million ≈ $115.94 Million |
-21.44% |
| 2017-12-31 | CHF116.73 Million ≈ $147.58 Million |
-14.04% |
| 2016-12-31 | CHF135.79 Million ≈ $171.68 Million |
-10.54% |
| 2015-12-31 | CHF151.79 Million ≈ $191.91 Million |
+2.23% |
| 2014-12-31 | CHF148.48 Million ≈ $187.72 Million |
+207.31% |
| 2013-12-31 | CHF48.32 Million ≈ $61.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Molecular Partners AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29770131800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Molecular Partners AG Net Assets Breakdown (December 2025)
Molecular Partners AG net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF4.04 Million | 5.03% |
| Other Components | CHF388.05 Million | 483.05% |
| Total Equity | CHF80.33 Million | 100.00% |
Molecular Partners AG Competitors by Market Cap
The table below lists competitors of Molecular Partners AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jindal Photo Limited
NSE:JINDALPHOT
|
$126.04 Million |
|
Amir Marketing and Investments in Agriculture Ltd
TA:AMRK
|
$126.08 Million |
|
Harbour Link Group Bhd
KLSE:2062
|
$126.09 Million |
|
The Metals Royalty Company Inc. Common Stock
NASDAQ:TMCR
|
$126.09 Million |
|
Arbor Technology
TWO:3594
|
$125.91 Million |
|
Ellington Residential Mortgage
NYSE:EARN
|
$125.86 Million |
|
Oncoclinicas do Brasil
SA:ONCO3
|
$125.85 Million |
|
Heritage Distilling Holding Company, Inc. Common Stock
NASDAQ:CASK
|
$125.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecular Partners AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 141,637,000 to 80,334,000, a change of -61,303,000 (-43.3%).
- Net loss of 61,651,000 reduced equity.
- Share repurchases of 63,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-61.65 Million | -76.74% |
| Share Repurchases | CHF63.00K | -0.08% |
| Other Changes | CHF411.00K | +0.51% |
| Total Change | CHF- | -43.28% |
Book Value vs Market Value Analysis
This analysis compares Molecular Partners AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.05x to 1.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CHF2.48 | CHF2.60 | x |
| 2014-12-31 | CHF9.71 | CHF2.60 | x |
| 2015-12-31 | CHF7.77 | CHF2.60 | x |
| 2016-12-31 | CHF6.65 | CHF2.60 | x |
| 2017-12-31 | CHF5.60 | CHF2.60 | x |
| 2018-12-31 | CHF4.33 | CHF2.60 | x |
| 2019-12-31 | CHF2.53 | CHF2.60 | x |
| 2020-12-31 | CHF4.29 | CHF2.60 | x |
| 2021-12-31 | CHF3.46 | CHF2.60 | x |
| 2022-12-31 | CHF7.07 | CHF2.60 | x |
| 2023-12-31 | CHF5.38 | CHF2.60 | x |
| 2024-12-31 | CHF4.16 | CHF2.60 | x |
| 2025-12-31 | CHF2.16 | CHF2.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecular Partners AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.27x
- Recent ROE (-76.74%) is below the historical average (-26.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.78% | 22.03% | 0.29x | 2.28x | CHF2.31 Million |
| 2014 | -1.54% | -8.57% | 0.14x | 1.31x | CHF-17.13 Million |
| 2015 | -0.10% | -0.51% | 0.13x | 1.45x | CHF-15.33 Million |
| 2016 | -13.71% | -80.78% | 0.13x | 1.36x | CHF-32.19 Million |
| 2017 | -21.79% | -127.05% | 0.14x | 1.24x | CHF-37.10 Million |
| 2018 | -40.39% | -357.66% | 0.07x | 1.69x | CHF-46.21 Million |
| 2019 | -67.03% | -178.03% | 0.19x | 1.94x | CHF-41.70 Million |
| 2020 | -58.54% | -671.70% | 0.05x | 1.75x | CHF-73.49 Million |
| 2021 | -59.45% | -683.65% | 0.05x | 1.61x | CHF-74.51 Million |
| 2022 | 50.11% | 62.17% | 0.72x | 1.12x | CHF94.34 Million |
| 2023 | -35.13% | -880.70% | 0.04x | 1.12x | CHF-79.63 Million |
| 2024 | -38.16% | -1087.38% | 0.03x | 1.12x | CHF-68.21 Million |
| 2025 | -76.74% | 0.00% | 0.00x | 1.27x | CHF-69.68 Million |
Industry Comparison
This section compares Molecular Partners AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $309,643,988
- Average return on equity (ROE) among peers: -22.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecular Partners AG (MOLN) | CHF58.54 Million | 14.78% | 0.29x | $125.91 Million |
| Addex Therapeutics Ltd (ADXN) | $16.29 Million | -165.85% | 0.33x | $3.89 Million |
| Bachem Holding AG (BANB) | $384.21 Million | 12.14% | 0.60x | $5.42 Billion |
| BB Biotech AG (BION) | $2.78 Billion | 20.81% | 0.00x | $2.90 Billion |
| Bioversys AG (BIOV) | $59.81 Million | -36.50% | 0.52x | $159.24 Million |
| Basilea Pharmaceutica AG (BSLN) | $127.94 Million | 31.42% | 1.20x | $686.09 Million |
| Idorsia Ltd (IDIA) | $-660.96 Million | 0.00% | 0.00x | $1.03 Billion |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $38.34 Million | -25.84% | 0.34x | $28.56 Million |
| Newron Pharmaceuticals SpA (NWRN) | $21.09 Million | -33.66% | 0.50x | $235.69 Million |
| Relief Therapeutics Holding AG (RLF) | $21.28 Million | -2.05% | 0.67x | $36.33 Million |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more